Related Experiment Video
Updated: Jan 13, 2026
08:18
A Model of Chronic Nutrient Infusion in the Rat
Published on: August 14, 2013
13.1K
Incretin effect is sufficient for glucose control in developing rats
The Journal of Endocrinology
|January 8, 2026
Summary
Incretin hormones stimulate insulin secretion in developing rat pups, similar to adults. Therapies targeting incretins, like DPP-4 inhibitors and GLP-1 receptor agonists, did not cause hypoglycemia, suggesting their potential safety for treating neonatal hyperglycemia.
Area of Science:
- Neonatal Physiology
- Endocrinology
- Pharmacology
Background:
- Neonatal hyperglycemia is common in preterm infants.
- Treatment requires a low risk of hypoglycemia.
- Incretin-based therapies offer a low hypoglycemia risk in adults.
Purpose of the Study:
- Investigate incretin hormone-enhanced insulin secretion in glucose regulation in rat pups.
- Evaluate the risk of hypoglycemia with incretin-based therapies in developing rats.
Main Methods:
- Oral glucose tolerance tests (OGTT) and intraperitoneal glucose tolerance tests (IPGTT) in 2-week-old Wistar rats.
- Comparison of serum glucose, insulin, and incretin hormone concentrations.
- Administration of a DPP-4 inhibitor (linagliptin) and a GLP-1 receptor agonist (liraglutide).
Main Results:
- The incretin effect was substantial (63%) in rat pups, with higher insulin secretion during OGTT compared to IPGTT.
- Therapeutic doses of linagliptin and liraglutide did not induce hypoglycemia in developing rats.
Conclusions:
- Endogenous incretin hormones stimulate insulin secretion in 2-week-old rats, mirroring adult responses.
- DPP-4 inhibitors and GLP-1 receptor agonists appear safe, without causing hypoglycemia in this model.
- Incretin-based therapies may represent a safe therapeutic strategy for neonatal hyperglycemia in preterm infants.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
832
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
832
01:23Dipeptidyl Peptidase 4 Inhibitors
574
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
574
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
2.1K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
2.1K
01:16Hormones Regulating Blood Glucose
6.4K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
6.4K
01:06Oral Hypoglycemic Agents: Glinides
585
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
585